Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]
Proposed [GID-TA10749] Expected publication date: TBC
Proposed [GID-TA10749] Expected publication date: TBC
Proposed [GID-TA10753] Expected publication date: TBC
Proposed [GID-TA10735] Expected publication date: TBC
We are listening to your views on this technology appraisal guidance. Comments close 04 March 2021.
Proposed [GID-TA10535] Expected publication date: TBC